<DOC>
	<DOCNO>NCT01509365</DOCNO>
	<brief_summary>The purpose study determine whether administration 150 mg clopidogrel effective reduce one-year incidence thromboischemic event patient high on-clopidogrel platelet reactivity compare 75 mg clopidogrel patient population overweight obese body mass index ( BMI ) ≥ 27 kg.m-2 .</brief_summary>
	<brief_title>Effect Platelet Inhibition According Clopidogrel Dose Patients With Body Mass Index ≥ 27</brief_title>
	<detailed_description>The goal evaluate effect double maintenance dose clopidogrel versus single dose patient proven coronary BMI ≥ 27 kg.m-2 1 - Biologically : study compare respective effect double dose single dose clopidogrel platelet aggregation . 2 - Clinically : study compare cardiovascular event adverse effect depend dose clopidogrel .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Male female , Old ( e ) 20 year BMI ≥ 27kg.m2 Patients hospitalize acute coronary syndrome ( Whatever ST segment troponin dosage ) Patients proven coronary candidate treatment Clopidogrel ( receive load dose 600mg 2 hour treat 75 mg/day 150mg / day clopidogrel longer 7 day ) Patients unwilling . Patient participate another study . Patients cardiogenic shock Patient anti GpIIbIIIa stop less 72 hour test aggregability Patients schedule surgery less 6 month ischemic stroke old 6 week . History hemorrhagic stroke ( time ) Patients candidate AVK Patients different anti ADP ( ticlopidine , prasugrel ) Patients indication clopidogrel ( side effect , bleed ... ) Thrombocytopenia &lt; 100000/mm3 anemia ( Ht &lt; 30 % ) Thrombocythaemia ( Ht &gt; 52 % ) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>cardiovascular disease</keyword>
	<keyword>maintenance dose</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>overweight</keyword>
	<keyword>antiplatelet agent</keyword>
</DOC>